TP53I11 Antibody

What is TP53I11 and what is its role in cellular processes?

TP53I11, also known as PIG11, is a 177 amino acid tumor suppressor belonging to the p53-induced protein gene (PIG) family. This family encodes redox-controlling proteins involved in p53 tumor suppressor activity. It is implicated in arsenic trioxide (As₂O₃)-induced apoptosis in certain cell lines and plays a significant role in tumor suppression through promotion of cell apoptosis. The gene encoding PIG11 maps to human chromosome 11, which houses over 1,400 genes and comprises nearly 4% of the human genome .

How does TP53I11 function in the p53 pathway?

TP53I11 functions as a downstream effector in the p53 signaling pathway. Upon activation of p53 (commonly through DNA damage, cellular stress, or oncogenic signals), p53 binds to response elements in the TP53I11 promoter region, inducing its transcription. Once expressed, TP53I11 contributes to p53-mediated apoptosis through redox-dependent mechanisms. This involvement in apoptotic pathways underscores its importance as a tumor suppressor, as impaired apoptosis is a hallmark of cancer development and progression .

What criteria should guide selection of a TP53I11 antibody for specific applications?

When selecting a TP53I11 antibody, researchers should consider:

For example, antibody ab234860 (Abcam) is a rabbit polyclonal validated for ICC/IF on human samples, while HPA061276 (Sigma/Atlas) is validated for immunofluorescence (0.25-2 μg/mL) and immunohistochemistry (1:200-1:500) .

How do I validate the specificity of a TP53I11 antibody?

Thorough validation requires multiple complementary approaches:

• Western blot analysis showing a single band of the expected molecular weight (~20-25 kDa for TP53I11)

• Testing in cell lines with known TP53I11 expression (e.g., HeLa cells)

• RNA interference experiments to confirm decreased signal following TP53I11 knockdown

• Peptide competition assays using the immunizing peptide

• Comparing results with multiple antibodies targeting different epitopes

• Positive controls (cell lines known to express TP53I11) and negative controls (secondary antibody only, isotype controls)

For instance, the specificity of anti-p53 antibody (Cat. No. 690039) was validated by Western blot analysis on HEK lysate, showing clear detection of the expected band .

What are the optimal protocols for TP53I11 detection by Western blot?

For optimal Western blot analysis of TP53I11:

• Sample preparation: Extract proteins using RIPA or NP-40 buffer containing protease inhibitors

• Protein loading: Load 20-30 μg of total protein per lane (20 μg was used successfully for HEK lysate)

• Gel electrophoresis: Use 12-15% SDS-PAGE (TP53I11 is relatively small)

• Transfer: PVDF membrane is recommended (as used for p53 detection)

• Blocking: 5% milk in PBST (PBS + 0.1% Tween 20) for 1 hour at room temperature

• Primary antibody: Dilute in blocking buffer (typically 1:500-1:2000); published protocols used anti-p53 at 25 ng/ml

• Incubation: 1 hour at room temperature or overnight at 4°C

• Secondary antibody: HRP-conjugated at appropriate dilution (typically 1:5000); one protocol used 200 ng/ml

• Detection: ECL substrate for visualization

When optimizing, create a titration series of antibody concentrations to determine optimal signal-to-noise ratio.

How should I optimize immunohistochemistry protocols for TP53I11 in FFPE tissues?

Optimization of IHC for TP53I11 in FFPE tissues requires:

• Antigen retrieval: Test both citrate buffer (pH 6.0) and EDTA buffer (pH 9.0); microwave treatment is recommended for some TP53I11 antibodies

• Blocking: 5-10% normal serum matching the secondary antibody species

• Primary antibody: Start with manufacturer's recommended dilution (typically 1:200-1:500 for TP53I11 antibodies)

• Incubation: Test both overnight (4°C) and shorter (1-2 hours, RT) incubations

• Detection system: Compare ABC, polymer-based, and tyramide amplification systems

• Counterstaining: Light hematoxylin for nuclear contrast

Include positive control tissues and negative controls (primary antibody omitted) in each experiment. For p53 detection in squamous cell carcinoma, antibody Bp53.11 has been successfully used at dilutions of 1:1000-1:3000 (17-50 ng/ml) .

What are best practices for immunofluorescence with TP53I11 antibodies?

For optimal immunofluorescence results:

• Cell preparation: Fix with 4% paraformaldehyde (10-15 minutes) followed by permeabilization with 0.1-0.5% Triton X-100

• Blocking: 1-5% BSA or normal serum for 30-60 minutes

• Primary antibody: Dilute according to manufacturer recommendations; ab234860 has been used successfully at 1/100 dilution

• Incubation: 1-2 hours at room temperature or overnight at 4°C

• Secondary antibody: Fluorophore-conjugated secondaries matched to your microscopy setup (e.g., Alexa Fluor 488-conjugated anti-rabbit IgG as used with ab234860)

• Counterstaining: DAPI for nuclear visualization

• Mounting: Anti-fade mounting medium to preserve fluorescence

For co-localization studies, include appropriate organelle markers and analyze using confocal microscopy.

How can I design experiments to study TP53I11 in p53-dependent apoptosis?

Design a comprehensive experimental approach:

• Cell model selection:

  • Use paired isogenic cell lines with/without functional p53

  • Include cell lines with different p53 status (wild-type, mutant, null)

• Apoptosis induction:

  • Treat cells with p53-activating stimuli (DNA damage inducers like doxorubicin)

  • Include arsenic trioxide (As₂O₃), which has been linked to TP53I11-mediated apoptosis

• Analysis methods:

  • Western blot for TP53I11, p53, and apoptosis markers (cleaved caspases)

  • qRT-PCR to measure TP53I11 mRNA induction

  • Immunofluorescence to examine localization changes

  • Flow cytometry for apoptosis quantification (Annexin V/PI)

• Functional studies:

  • Overexpress TP53I11 to test if it induces apoptosis independent of p53

  • Use siRNA/CRISPR to knock down TP53I11 and test effect on p53-dependent apoptosis

  • Perform rescue experiments in p53-null cells

Include appropriate time-course experiments to capture the temporal dynamics of p53 activation and subsequent TP53I11 induction.

How can I detect post-translational modifications of TP53I11?

Detecting post-translational modifications (PTMs) of TP53I11 requires specialized approaches:

• Modification-specific antibodies:

  • Use antibodies against predicted PTMs of TP53I11

  • Consider developing custom antibodies against modified peptides

• Enrichment strategies:

  • Immunoprecipitate TP53I11 first, then probe with antibodies against common modifications

  • Use phospho-protein enrichment methods before Western blotting

• 2D gel electrophoresis:

  • Separate proteins based on isoelectric point (affected by PTMs) and molecular weight

  • Follow with Western blotting using TP53I11 antibodies

• Mass spectrometry:

  • Immunoprecipitate TP53I11 and analyze by LC-MS/MS

  • Look for mass shifts corresponding to specific modifications

• Functional validation:

  • Use phosphatase or deacetylase treatments to confirm specificity

  • Compare PTM patterns after treatment with p53-activating stimuli

When studying PTMs, remember that modifications might affect antibody binding, potentially leading to false-negative results if epitopes overlap with modification sites.

What strategies can address weak or non-specific signals with TP53I11 antibodies?

For weak signals:

• Increase protein concentration (for Western blots)

• Extend primary antibody incubation time

• Optimize antigen retrieval conditions for IHC/ICC

• Use signal amplification systems

• Try concentrating the sample through immunoprecipitation

• Test more sensitive ECL reagents

For non-specific signals:

• Increase blocking stringency (longer blocking, different blocking agents)

• Optimize washing (more frequent or longer washes)

• Dilute primary antibody further

• Pre-adsorb the antibody with control lysates

• Test monoclonal antibodies for higher specificity

• Include competitive peptide controls

• Change detection method (fluorescence vs. chromogenic for IHC)

Always validate results using orthogonal detection methods and include appropriate controls in each experiment.

How should I interpret variations in TP53I11 expression across different cancer types?

When analyzing TP53I11 expression variations:

• Quantification methods:

  • Use standardized scoring systems for IHC (H-score, Allred score)

  • For Western blots, normalize to housekeeping proteins

  • Apply appropriate normalization to gene expression data

• Correlative analysis:

  • Compare TP53I11 expression with p53 mutation status

  • Analyze relationship with clinical parameters (stage, grade, outcome)

  • Assess correlation with other p53 pathway components

• Contextual interpretation:

  • Consider tissue-specific baseline expression levels

  • Evaluate expression in tumor cells versus stroma

  • Compare with matched normal tissue when available

• Integrative assessment:

  • Combine protein data with transcript-level information

  • Incorporate genomic data affecting the TP53I11 locus

  • Consider epigenetic regulation (promoter methylation)

For example, p53 R175H (R172H in mice) is a hotspot mutation in various cancer types , and TP53I11 expression patterns may correlate with this mutation status across different cancers.